Sirtris aims to cash in on resveratrol buzz

Analysts say that all the attention being paid to the healthy effects of resveratrol should boost Sirtris' efforts to push through an IPO it hopes will raise up to $60 million. Sirtris is focused on advancing sirtuin drugs to treat metabolic disorders like Type 2 diabetes and other age and diet-related diseases. But with only one drug in an early-stage trial, Cambridge, MA-based Sirtris is heading for the market at a much earlier stage than most biotechs would contemplate these days.

- here's the AP report on the Sirtris IPO

Related Articles:
Sirtris pockets $37M in venture funds. Report
Sirtris, Helicos file IPOs. Report
Resveratrol may boost longevity, health. Report